Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Consulting agrmnt
Director departure
Quarterly results
Appointed director
CC transcript
Inv. presentation
|
|
MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/19/2019 |
RW
| Form RW - Registration Withdrawal Request: |
| 05/09/2019 |
SC 13G/A
| Opko Health, Inc. reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC. |
| 04/24/2019 |
10-Q/A
| Quarterly Report for the period ended September 30, 2018 [amend] |
| 03/29/2019 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 03/29/2019 |
10-Q/A
| Quarterly Report for the period ended September 30, 2018 [amend] |
| 03/25/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
| 01/04/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/20/2018 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 11/20/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 11/13/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 10/22/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 10/16/2018 |
8-K
| Quarterly results |
| 10/15/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
| 10/15/2018 |
10-Q
| Quarterly Report for the period ended March 31, 2018 |
| 10/15/2018 |
10-K/A
| Annual Report for the period ended December 31, 2017 [amend] |
| 09/27/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 08/06/2018 |
SC 13G
| Honig Barry C reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC. |
| 08/02/2018 |
GN
| DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline – August 3, 2018 |
| 07/26/2018 |
GN
| FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX) To Contact The Firm |
| 07/25/2018 |
SC 13D/A
| Stetson John reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC. |
| 07/12/2018 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MabVax Therapuetics Holdings, Flex Pharma, Inc. and Ormat Technologies, Inc. and Encourages Investors to Contact the Firm |
| 07/09/2018 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits |
| 07/06/2018 |
GN
| MBVX LOSS ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against MabVax Therapeutics Holdings, Inc. – MBVX |
| 07/05/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...|
Docs:
|
"MabVax Therapeutics Receives Nasdaq Delist Determination San Diego, CA, July 5, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that as a result of the Company’s decision not to submit a plan to regain compliance with Nasdaq’s filing requirement, which decision was announced by the Company in a press release on July 2, 2018, on that same date, the Listing Qualifications Staff of The Nasdaq Stock Market LLC notified the Company of its determination to delist the Company’s securities from Nasdaq. The Staff indicated that the determination was based upon the Company’s non-compliance wi..." |
|
| 07/03/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 07/02/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 06/29/2018 |
GN
| MabVax Shareholder Class Action: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against MabVax Therapeutics Holdings, Inc. - MBVX |
| 06/29/2018 |
GN
| LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MabVax Therapeutics Holdings, Inc. To Contact The Firm |
| 06/29/2018 |
GN
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline – August 3, 2018 |
| 06/28/2018 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against MabVax Therapeutics Holdings, Inc. (MBVX) and Encourages Investors to Contact the Firm |
| 06/26/2018 |
GN
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit |
| 06/15/2018 |
GN
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline – August 3, 2018 |
| 06/06/2018 |
GN
| SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX) To Contact Brower Piven Before The Lead Plaintiff Deadline |
| 06/05/2018 |
GN
| Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against MabVax Therapeutics Holdings, Inc. (MBVX) |
|
|
|